Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

"GLP-1 medications are currently the most effective weight loss adjunct available if the patient does not meet the criteria ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Americans shelled out an estimated $71 billion for weight-loss drugs in 2023 - that is as much as the U.S. government disbursed in foreign aid the same year, according to ForeignAssistance.gov.